A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat

A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma

Sponsor(s)

Novartis Pharmaceuticals Corporation

Principal Investigator(s)Jonathan L Kaufman, MD
Dates10/25/2010 - 10/24/2014